Remdesivir

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Feb 12, 2021 → Apr 30, 2021

NCT ID

NCT04847622

About Remdesivir

Remdesivir is a pre-clinical stage product being developed by Gilead Sciences for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04847622. Target conditions include Covid19.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04323761	Pre-clinical	Completed	—	—	SARS-CoV2 Infection
NCT06817889	Phase 2	Recruiting	Dec 23, 2025	Nov 30, 2027	Hematopoietic and Lymphatic System Neoplasm
NCT04582266	Pre-clinical	Completed	Mar 31, 2021	Apr 13, 2022	COVID-19
NCT04847622	Pre-clinical	Completed	Feb 12, 2021	Apr 30, 2021	Covid19
NCT04431453	Phase 2/3	Completed	Jul 21, 2020	Feb 10, 2023	COVID-19

Competing Products

20 competing products in Covid19

See all competitors

Product	Company	Stage	Hype Score
Favipiravir + Nitazoxanide	Strides Pharma	Phase 2	51
Icosapent ethyl	Amarin Corporation	Approved	77
GX-03 + Petrolatum ointment	Turn Therapeutics	Phase 2	44
Cytotoxic T Lymphocytes	Tevogen Bio	Phase 1	25
DS-5670a + Placebo	Daiichi Sankyo	Phase 1/2	41
Pegylated Interferon-α2b	Zydus Lifesciences	Phase 2	52
Baricitinib	Eli Lilly	Phase 3	77
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814	Eli Lilly	Phase 3	77
bamlanivimab	Eli Lilly	Approved	85
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222	AstraZeneca	Phase 1	33
Sacubitril / Valsartan Oral Tablet [Entresto] + Placebo	Novartis	Phase 1/2	41
Pirfenidone	Roche	Pre-clinical	23
Remdesivir + Remdesivir Placebo + Corticosteroid	Gilead Sciences	Phase 3	76
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + Corticosteroid	Gilead Sciences	Phase 3	76
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)	Pfizer	Phase 3	76
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 Vaccine	Pfizer	Pre-clinical	22
Tofacitinib 10 mg + Placebo	Pfizer	Phase 3	76
BNT162b2	Pfizer	Phase 2	51
Anakinra + 0.9% Saline	Swedish Orphan Biovitrum	Phase 2	51
COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)	Sanofi	Approved	84

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved

Truvada + Atazanavir + RitonavirApproved

Truvada + efavirenzApproved

B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved

TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved